Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.

导出 LinkOut

翻译打印收藏纠错

作者： Marja K,Puurunen ^[1] ; Jerry,Vockley ^[2] ; Shawn L,Searle ^[3] ; Stephanie J,Sacharow ^[4] ; John A,Phillips ^[5] ; William S,Denney ^[6] ; Benjamin D,Goodlett ^[7] ; David A,Wagner ^[8] ; Larry,Blankstein ^[5] ; Mary J,Castillo ^[6] ; Mark R,Charbonneau ^[9] ; Vincent M,Isabella ^[10] ; Vasu V,Sethuraman ^[10] ; Richard J,Riese ^[10] ; Caroline B,Kurtz ^[10] ; Aoife M,Brennan ^[10]

作者单位： Synlogic, Inc., Cambridge, MA, USA. marja@synlogictx.com. ^[1] University of Pittsburgh, Pittsburgh, PA, USA. ^[2] UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA. ^[3] PRA Health Sciences, Salt Lake City, UT, USA. ^[4] Boston Children's Hospital, Boston, MA, USA. ^[5] Harvard Medical School, Boston, MA, USA. ^[6] Vanderbilt University Medical Center, Nashville, TN, USA. ^[7] Human Predictions LLC, Boston, MA, USA. ^[8] Metabolic Solutions, Nashua, NH, USA. ^[9] Synlogic, Inc., Cambridge, MA, USA. ^[10]

DOI 10.1038/s42255-022-00635-4

PMID 35974248

发布时间 2022-09-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Nature metabolism

2022年4卷9期

1214页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.

Nature metabolism

相似文献

Nature metabolism

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.

Nature metabolism

相似文献

Nature metabolism

相关期刊

检索历史清除